$APRE News

Aprea Therapeutics Presents Updated Phase 1 Data on WEE1 Inhibitor APR-1051 at ASCO 2026, Demonstrating Early Monotherapy Activity and Manageable Tolerability in Advanced Solid Tumors

Aprea Therapeutics Presents Early Results From Its First-In-Human Phase 1 Trial Of WEE1 Inhibitor APR-1051 In Participants With Advanced Solid Tumors

Wedbush Maintains Outperform on Aprea Therapeutics, Lowers Price Target to $6

Aprea Therapeutics (NASDAQ:APRE) Q1 2026 Results: Clinical Progress Drives Stock Higher

Aprea Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Aprea Therapeutics Q1 EPS $(0.22) Beats $(0.23) Estimate

Oppenheimer Initiates Coverage On Aprea Therapeutics with Outperform Rating, Announces Price Target of $5

Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting

Aprea Therapeutics To Present Abstract Titled 'Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)' At 2026 American Society Of Clinical Oncology Annual Meeting

Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private Placement

Wedbush Reiterates Outperform on Aprea Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. Maintains Buy on Aprea Therapeutics, Lowers Price Target to $1.2

Aprea Therapeutics Announces Oversubscribed $30 Million Private Placement

Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 Trial

Aprea Therapeutics Commences ~$30M Offering Of Warrants, Pre-Funded Warrants

Aprea Therapeutics Announces Confirmation Of A Partial Response In Ongoing Phase 1 APR-1051 Evaluation, A Selective WEE1 Kinase Inhibitor

Aprea Therapeutics Announces Confirmation Of A Partial Response In Ongoing Phase 1 APR-1051 Evaluation, A Selective WEE1 Kinase Inhibitor

Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update

Aprea Therapeutics Q4 EPS $(0.32) Misses $(0.30) Estimate, Sales $3.337K Down From $205.817K YoY

12 Health Care Stocks Moving In Tuesday's After-Market Session